Kennedy’s BIG Move: CDC Changes Course

CDC BOMBSHELL

Marking a dramatic shift away from the previous administration’s aggressive pediatric vaccination push, the Food and Drug Administration (FDA) is considering revoking authorization for Pfizer’s COVID-19 vaccine in healthy children under 5.

Story Snapshot

FDA weighs pulling Pfizer’s COVID vaccine authorization for healthy children aged 6 months to 4 years.
Decision not based on safety concerns but reflects broader policy shift under HHS Secretary Robert F. Kennedy Jr.
CDC already removed routine COVID vaccination recommendations for healthy children in May 2025.
The move could leave young children with limited vaccine options, as Moderna and Novavax have restricted pediatric authorizations.

Policy Reversal Under New Leadership

The FDA’s deliberation represents a fundamental departure from Biden-era vaccine policies that pushed universal pediatric COVID vaccination.

Under HHS Secretary Robert F. Kennedy Jr., federal health agencies are reassessing pediatric immunization strategies based on actual risk-benefit analysis rather than one-size-fits-all mandates.

This evidence-based approach acknowledges what many parents and physicians have long argued: healthy young children face minimal risk from COVID-19.

CDC Abandons Universal Child Vaccination Push

The CDC’s May 2025 guidance shift eliminated routine COVID vaccination recommendations for healthy children and pregnant women, stating vaccines “may” be given if physicians deem necessary.

This discretionary approach respects parental choice and medical judgment over bureaucratic mandates. The policy change reflects growing recognition that blanket vaccination policies failed to account for individual risk factors and natural immunity considerations.

Limited Vaccine Options Remain

If Pfizer’s authorization is revoked, parents seeking COVID-19 vaccination for young children would face restricted options. Moderna’s vaccine maintains full approval only for high-risk children with underlying conditions, while Novavax’s protein-based vaccine remains unavailable for children under 12.

This situation underscores the previous administration’s overreliance on emergency authorizations rather than thorough safety and efficacy evaluations for different age groups.

Pfizer continues discussions with the FDA to maintain authorization for the upcoming season, though the company acknowledges the deliberations aren’t related to new safety or efficacy concerns.

The pharmaceutical giant’s efforts to preserve market access highlight the financial incentives that drove aggressive pediatric vaccination campaigns despite limited clinical benefit for healthy children.

Restoring Parental Rights and Medical Freedom

The potential authorization withdrawal represents a victory for parental rights advocates who fought against coercive vaccination policies targeting low-risk children.

Parents and pediatricians can now make informed decisions based on individual circumstances rather than federal mandates driven by pharmaceutical lobbying and political pressure.

This common-sense approach prioritizes individual liberty while maintaining access for truly high-risk children who may benefit from vaccination.

Incredible it was ever suggested.

FDA may pull authorization of Pfizer's Covid vaccine for children under 5, company says https://t.co/rVzbEu6i9p

— WestTNBarBQ 🐊 (@WestTNBarBQ) August 13, 2025

The broader implications extend beyond COVID vaccines to future federal health policies. Kennedy’s leadership signals a return to evidence-based medicine that considers actual disease risk, individual health status, and informed consent principles.

This policy shift protects constitutional rights while ensuring vulnerable populations receive appropriate medical interventions based on scientific evidence rather than political expediency.